Research progress of immunotherapy in esophageal squamous cell carcinoma

doi:10.3760/cma.j.cn371439-20200708-00082

Abstract

Abstract:

With the development of immunotherapy in clinical application, immunotherapy also takes advantage in esophageal squamous cell carcinoma (ESCC). Immune checkpoint inhibitors such as programmed death-1 (PD-1) and its ligand PD-L1 and cytotoxic T lymphocyte antigen-4 show significant antitumor activity and safety in immunotherapy for patients with advanced ESCC.

Key words: Esophageal neoplasms, Immunotherapy, T-lymphocytes,cytotoxic, Programmed death-1, Immune checkpoint inhibitor

Yang Wenqian, Huang Junxing. Research progress of immunotherapy in esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2021, 48(7): 429-432.

References 39

[1]	Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline[J]. J Clin Oncol, 2016, 34(6):611-635. DOI: 10.1200/JCO.2015.64.3809. doi: 10.1200/JCO.2015.64.3809 pmid: 26644543
[2]	Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esopha-geal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries[J]. World J Gastroenterol, 2015, 21(26):7933-7943. DOI: 10.3748/wjg.v21.i26.7933. doi: 10.3748/wjg.v21.i26.7933
[3]	Dutton SJ, Ferry DR, Blazeby JM, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial[J]. Lancet Oncol, 2014, 15(8):894-904. DOI: 10.1016/S1470-2045(14)70024-5. doi: 10.1016/S1470-2045(14)70024-5
[4]	Hirano H, Kato K. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy[J]. Jpn J Clin Oncol, 2019, 49(5):412-420. DOI: 10.1093/jjco/hyz034. doi: 10.1093/jjco/hyz034
[5]	Fatehi Hassanabad A, Chehade R, Breadner D, et al. Esophageal carcinoma: towards targeted therapies[J]. Cell Oncol (Dordr), 2020, 43(2):195-209. DOI: 10.1007/s13402-019-00488-2.
[6]	Jiao R, Luo H, Xu W, et al. Immune checkpoint inhibitors in eso-phageal squamous cell carcinoma: progress and opportunities[J]. Onco Targets Ther, 2019, 12:6023-6032. DOI: 10.2147/OTT.S214579. doi: 10.2147/OTT
[7]	Haanen JB, Robert C. Immune checkpoint inhibitors[J]. Prog Tumor Res, 2015, 42:55-66. DOI: 10.1159/000437178. doi: 10.1159/000437178 pmid: 26382943
[8]	Mimura K, Yamada L, Ujiie D, et al. Immunotherapy for esophageal squamous cell carcinoma: a review[J]. Fukushima J Med Sci, 2018, 64(2):46-53. DOI: 10.5387/fms.2018-09. doi: 10.5387/fms.2018-09
[9]	Rong L, Liu Y, Hui Z, et al. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population[J]. Diagn Pathol, 2019, 14(1):6. DOI: 10.1186/s13000-019-0778-4. doi: 10.1186/s13000-019-0778-4
[10]	Garcia-Perez JE, Baxter RM, Kong DS, et al. CTLA4 message reflects pathway disruption in monogenic disorders and under therapeutic blockade[J]. Front Immunol, 2019, 10:998. DOI: 10.3389/fimmu.2019.00998. doi: 10.3389/fimmu.2019.00998 pmid: 31156616
[11]	Sunshine J, Taube JM. PD-1/PD-L1 inhibitors[J]. Curr Opin Pharmacol, 2015, 23:32-38. DOI: 10.1016/j.coph.2015.05.011. doi: 10.1016/j.coph.2015.05.011 pmid: 26047524
[12]	Kato K, Doki Y, Ura T, et al. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer[J]. Cancer Sci, 2020, 111(5):1676-1684. DOI: 10.1111/cas.14380. doi: 10.1111/cas.v111.5
[13]	Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2017, 18(5):631-639. DOI: 10.1016/S1470-2045(17)30181-X. doi: 10.1016/S1470-2045(17)30181-X
[14]	Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemothe-rapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(11):1506-1517. DOI: 10.1016/S1470-2045(19)30626-6. doi: 10.1016/S1470-2045(19)30626-6
[15]	Kwok G, Yau TC, Chiu JW, et al. Pembrolizumab (Keytruda)[J]. Hum Vaccin Immunother, 2016, 12(11):2777-2789. DOI: 10.1080/21645515.2016.1199310. doi: 10.1080/21645515.2016.1199310
[16]	Salik B, Smyth MJ, Nakamura K. Targeting immune checkpoints in hematological malignancies[J]. J Hematol Oncol, 2020, 13(1):111. DOI: 10.1186/s13045-020-00947-6. doi: 10.1186/s13045-020-00947-6
[17]	Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(6):821-831. DOI: 10.1016/S1470-2045(20)30169-8. doi: 10.1016/S1470-2045(20)30169-8
[18]	Joshi SS, Maron SB, Catenacci DV. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma[J]. Future Oncol, 2018, 14(5):417-430. DOI: 10.2217/fon-2017-0436. doi: 10.2217/fon-2017-0436
[19]	Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma[J]. J Clin Oncol, 2018, 36(1):61-67. DOI: 10.1200/JCO.2017.74.9846.
[20]	Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study[J]. JAMA Oncol, 2019, 5(4):546-550. DOI: 10.1001/jamaoncol.2018.5441. doi: 10.1001/jamaoncol.2018.5441
[21]	Kato K, Shah MA, Enzinger P, et al. KEYNOTE-590: phase Ⅲ study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer[J]. Future Oncol, 2019, 15(10):1057-1066. DOI: 10.2217/fon-2018-0609. doi: 10.2217/fon-2018-0609 pmid: 30735435
[22]	Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and Esopha-gogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2019, 17(7):855-883. DOI: 10.6004/jnccn.2019.0033. doi: 10.6004/jnccn.2019.0033
[23]	Zayac A, Almhanna K. Esophageal, gastric cancer and immunothe-rapy: small steps in the right direction?[J]. Transl Gastroenterol Hepatol, 2020, 5:9. DOI: 10.21037/tgh.2019.09.05. doi: 10.21037/tgh.2019.09.05 pmid: 32190777
[24]	Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinu-metoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. doi: S0140-6736(19)32222-6 pmid: 31590988
[25]	Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study[J]. Br J Cancer, 2018, 119(5):538-545. DOI: 10.1038/s41416-018-0100-3. doi: 10.1038/s41416-018-0100-3
[26]	Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018, 24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439. doi: 10.1158/1078-0432.CCR-17-2439 pmid: 29358502
[27]	Wang X, Zhang B, Chen X, et al. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esopha-geal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody[J]. Thorac Cancer, 2019, 10(6):1395-1401. DOI: 10.1111/1759-7714.13083. doi: 10.1111/1759-7714.13083 pmid: 31017739
[28]	Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition[J]. Am J Clin Oncol, 2016, 39(1):98-106. DOI: 10.1097/COC.000000000-0000239. doi: 10.1097/COC.0000000000000239
[29]	Simsek M, Tekin SB, Bilici M. Immunological agents used in cancer treatment[J]. Eurasian J Med, 2019, 51(1):90-94. DOI: 10.5152/eurasianjmed.2018.18194. doi: 10.5152/eurasianjmed.
[30]	Meindl-Beinker NM, Betge J, Gutting T, et al. A multicenter open-label phase Ⅱ trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)[J]. BMC Cancer, 2019, 19(1):231. DOI: 10.1186/s12885-019-5446-2. doi: 10.1186/s12885-019-5446-2 pmid: 30871493
[31]	Kelly RJ, Lee J, Bang YJ, et al. Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma[J]. Clin Cancer Res, 2020, 26(4):846-854. DOI: 10.1158/1078-0432.CCR-19-2443.
[32]	Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors[J]. Mol Cancer, 2018, 17(1):129. DOI: 10.1186/s12943-018-0864-3. doi: 10.1186/s12943-018-0864-3
[33]	Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030):1837-1846. DOI: 10.1016/S0140-6736(16)00587-0. doi: 10.1016/S0140-6736(16)00587-0 pmid: 26970723
[34]	Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human can-cers and its association with clinical outcomes[J]. Onco Targets Ther, 2016, 9:5023-5039. DOI: 10.2147/OTT.S105862. doi: 10.2147/OTT
[35]	Ritterhouse LL. Tumor mutational burden[J]. Cancer Cytopathol, 2019, 127(12):735-736. DOI: 10.1002/cncy.22174. doi: 10.1002/cncy.22174 pmid: 31433548
[36]	Mazloom A, Ghalehsari N, Gazivoda V, et al. Role of immune checkpoint inhibitors in gastrointestinal malignancies[J]. J Clin Med, 2020, 9(8):2533. DOI: 10.3390/jcm9082533. doi: 10.3390/jcm9082533
[37]	Fabrizio DA, George TJ Jr, Dunne RF, et al. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition[J]. J Gastrointest Oncol, 2018, 9(4):610-617. DOI: 10.21037/jgo.2018.05.06. doi: 10.21037/jgo.2018.05.06 pmid: 30151257
[38]	Mrabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1):1-10. DOI: 10.1200/JCO.19.02105.
[39]	Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349):409-413. DOI: 10.1126/science.aan6733. doi: 10.1126/science.aan6733